A novel ceftazidime-hydrolysing extended-spectrum β-lactamase, CTX-M-54, with a single amino acid substitution at position 167 in the omega loop

被引:40
作者
Bae, Il Kwon
Lee, Byung Ho
Hwang, Hyun Yong
Jeong, Seok Hoon
Hong, Seong Geun
Chang, Chulhun L.
Kwak, Hyo-Sun
Kim, Hyoung Jin
Youn, Hasik
机构
[1] Kosin Univ, Coll Med, Dept Lab Med, Pusan 602030, South Korea
[2] Pochon CHA Univ, Coll Med, Dept Lab Med, Sungnam 463712, South Korea
[3] Pusan Natl Univ, Sch Med, Dept Lab Med, Pusan 602739, South Korea
[4] Korea Food & Drug Adm, Ctr Food Safety Evaluat, Seoul 122704, South Korea
[5] LG Life Sci Ltd, Taejon 305380, South Korea
关键词
cefotaximase; ISEcp1; IS903;
D O I
10.1093/jac/dkl252
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To characterize a novel ceftazidime-hydrolysing CTX-M mutant, designated CTX-M-54, produced by Klebsiella pneumoniae clinical isolate BDK0419 and to investigate its genetic environment. Methods: Antimicrobial susceptibilities were determined by disc diffusion and agar dilution methods, and the double-disc synergy test was carried out. Detection of genes encoding class A beta-lactamases was performed by PCR amplification, and the genetic organization of the bla(CTX-M-54) gene was investigated by PCR and sequencing of the regions surrounding this gene. Kinetic parameters were determined from purified CTX-M-54. Results: The strain BDK0419 contained a transferable plasmid with a molecular size of similar to 21 kbp that carries both bla(SHV-2a) and bla(CTX-M-54) beta-lactamase genes, along with two other plasmids. The bla(CTX-M-54) gene was flanked upstream by an ISEcp1 insertion sequence and downstream by an IS903-like element. CTX-M-54 had a P167Q substitution within the omega loop region of class A beta-lactamases compared with the sequence of CTX-M-3. The MIC of ceftazidime for K. pneumoniae BDK0419 was 16-fold higher than that of cefotaxime; however, the kinetic parameter of CTX-M-54 against ceftazidime revealed a low catalytic efficiency. Conclusions: This work shows once again that novel CTX-M enzymes with an expanded activity towards ceftazidime through a single amino acid substitution can be identified from clinical isolates. Thus, detection of CTX-M enzymes can no longer be based solely on the resistance phenotypes of clinical isolates towards ceftazidime and cefotaxime.
引用
收藏
页码:315 / 319
页数:5
相关论文
共 15 条
[1]   Effect of D240G substitution in a novel ESBL CTX-M-27 [J].
Bonnet, R ;
Recule, C ;
Baraduc, R ;
Chanal, C ;
Sirot, D ;
De Champs, C ;
Sirot, J .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (01) :29-35
[2]   Novel cefotaximase (CTX-M-16) with increased catalytic efficiency due to substitution Asp-240→Gly [J].
Bonnet, R ;
Dutour, C ;
Sampaio, JLM ;
Chanal, C ;
Sirot, D ;
Labia, R ;
De Champs, C ;
Sirot, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (08) :2269-2275
[3]   Growing group of extended-spectrum β-lactamases:: The CTX-M enzymes [J].
Bonnet, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (01) :1-14
[4]   ColE1-Like plasmid pIP843 of Klebsiella pneumoniae encoding extended-spectrum β-lactamase CTX-M-17 [J].
Cao, V ;
Lambert, T ;
Courvalin, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (05) :1212-1217
[5]  
Clinical and Laboratory Standards Institute, 2006, PERF STAND ANT DISK
[6]  
Clinical and Laboratory Standards Institute, 2006, METH DIL ANT SUSC TE
[7]  
JARLIER V, 1988, REV INFECT DIS, V10, P867
[8]   Characterization of a new integron containing VIM-2, a metallo-β-lactamase gene cassette, in a clinical isolate of Enterobacter cloacae [J].
Jeong, SH ;
Lee, K ;
Chong, YS ;
Yum, JH ;
Lee, SH ;
Choi, HJ ;
Kim, JM ;
Park, KH ;
Han, BH ;
Lee, SW ;
Jeong, TS .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (02) :397-400
[9]   Role of a mutation at position 167 of CTX-M-19 in ceftazidime hydrolysis [J].
Kimura, S ;
Ishiguro, M ;
Ishii, Y ;
Alba, J ;
Yamaguchi, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (05) :1454-1460
[10]   ISEcp1B-mediated transposition of blaCTX-M in Escherichia coli [J].
Poirel, L ;
Lartigue, MF ;
Decousser, JW ;
Nordmann, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (01) :447-450